Discover how Evelo’s EDP1815 may prevent the progression of COVID-19. Learn More

skip to content

Evelo Biosciences Announces Dosing of First Patient in Investigator-Sponsored Phase 2a Clinical Trial of EDP1503 in Combination with KEYTRUDA® in Patients with Metastatic Melanoma

Cambridge, Mass. - January 28, 2019

Read the original article here